JAMA Oncology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019.
8.
2021
-
Metformin—A Thought-Provoking Addition to Anticancer Therapies—Reply.
8.
2021
-
Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes.
7:1806-1806.
2021
-
Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non–Small Cell Lung Cancer.
7:1324-1324.
2021
-
Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer.
7:1333-1333.
2021
-
Central Nervous System–Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma.
7:1062-1062.
2021
-
Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma.
7:773-773.
2021
-
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer.
6:1751-1751.
2020
-
Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplant and Lymphoma.
6:989-989.
2020
-
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer.
6:831-831.
2020
-
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
6:505-505.
2020
-
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017.
5:1749-1749.
2019
-
Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With “Good Prognosis” Rectal Cancer Eligible for Primary Surgery.
5:961-961.
2019
-
Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy.
5:664-664.
2019
-
Therapeutic Options for Neuroendocrine Tumors.
5:480-480.
2019
-
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016.
4:1553-1553.
2018
-
Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
4:1059-1059.
2018
-
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma.
3:913-913.
2017
-
Effect of Radiotherapy on Painful Bone Metastases.
3:953-953.
2017
-
Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma.
3:366-366.
2017
-
Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma.
3:220-220.
2017
-
Clarifying Assumptions and Outcomes in Cost-Effectiveness Analyses—Reply.
2:278-278.
2016
-
Cost-effectiveness of Lung Cancer Screening in Canada.
1:807-807.
2015
-
The Global Burden of Cancer 2013.
1:505-505.
2015
-
Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
1:359-359.
2015
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)